NCT07198074 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07198074
Title	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Recruitment	Recruiting
Gender	female
Phase	Phase III
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	endometrial cancer endometrial adenocarcinoma endometrial serous adenocarcinoma endometrial mixed adenocarcinoma endometrial clear cell adenocarcinoma uterine carcinosarcoma
Therapies	Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST